MediBeacon

MediBeacon is focused on advancing fluorescent tracer agents and transdermal detection technology to provide vital and actionable measurement of organ function.

[MediBeacon @medibeacon]

Learn about the Transdermal GFR System (TGFR) @ERAkidney June 4-7. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin) injection which together allow assessment of kidney function. For more information, please visit https://t.co/W2f2LDsavF.

[MediBeacon @medibeacon]

Peer-reviewed articles from MediBeacon clinical studies published in Clinical Kidney Journal https://t.co/I4DOXeENYO JASN https://t.co/M9GSfkuH4m in advance of Transdermal GFR System (TGFR) device approval in China. See press release https://t.co/PLEKOYApQo.

[MediBeacon @medibeacon]

FDA approves Transdermal GFR System (TGFR). See https://t.co/E0Sm7j0w7k. TGFR Sensor, TGFR Monitor, and Lumitrace®(relmapirazin) injection together allow kidney function assessment by measuring clearance rate of fluorescent agent as it leaves body. See https://t.co/W2f2LDsavF.

[MediBeacon @medibeacon]

MediBeacon announces a peer-reviewed article publication in Kidney International of data from pilot, multi-center clinical study comparing plasma-derived GFR of our novel fluorescent tracer agent relmapirazin (MB-102) to plasma-derived GFR of iohexol. See https://t.co/dEheJAGd12

[MediBeacon @medibeacon]

A United States patent was granted to MediBeacon Inc. on July 30, 2024, covering additional aspects of the Company’s GI permeability measurement platform development program.

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us at @ERAkidney May 23-26.

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @APS2024 April 4-7.

[MediBeacon @medibeacon]

Clinical gut permeability assessment in Crohn’s Disease Patients using relmapirazin (MB-102) MediBeacon fluorophore technology published GastroHep Advances https://t.co/McRTX5GSyo

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @ASNKidney Week November 1-5.

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >450 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us at @ERAkidney Congress June 15-18

[MediBeacon @medibeacon]

MediBeacon appoints Dr. Steve Miller Chief Medical Officer as enrollment in Phase 3 study focused on kidney disease is completed. Dr. Miller formerly served as Cigna EVP and Chief Clinical Officer and has been on MediBeacon’s Board of Directors since 2015. https://t.co/dJdGCMX0By

[MediBeacon @medibeacon]

Second peer-reviewed paper on applicability of using novel fluorescent tracer agent relmapirazin (MB-102) in CRRT is online at ASAIO Journal. Changes in transdermal detected relmapirazin clearance occurred immediately with a change in CRRT rates. https://t.co/VFQiGImElQ

[MediBeacon @medibeacon]

Peer-reviewed paper on applicability of using novel fluorescent tracer agent relmapirazin (MB-102) in CRRT is online at ASAIO Journal. No adsorption of agent observed on any component of typical CRRT apparatus in the in vitro experiments reported herein. https://t.co/HH4dJr1SFT

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications w/ >400 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @APSPhysiology Summit April 20-23

[MediBeacon @medibeacon]

Chief Scientific Officer Richard B. Dorshow, PhD gave a presentation at the 2023 Biomedical Optics Conference (BiOS) @PhotonicsWest entitled “Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement”.

[MediBeacon @medibeacon]

MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System and is approaching completion of Phase 3 study focused on kidney disease #pharmaceuticals #kidneydisease #renal #CKD https://t.co/weYfn59qcB

[MediBeacon @medibeacon]

MediBeacon to present @ASNKidney week 2022 “Transdermal Glomerular Filtration Rate Measurement: Clinical Results from a Pilot Multi-Center Study Establishing Feasibility and Efficacy” on Thursday Nov. 3, 2022 at 4:30 PM (ET). Pub# TH-OR38, Learn more https://t.co/tjrplb77oZ

[MediBeacon @medibeacon]

Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) is being shown to have many preclinical applications w/ >350 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt7AK6 See us @ASNKidney Week

[MediBeacon @medibeacon]

New chiral chromatography method developed to determine chiral purity of Relmapirazin (MB-102). See https://t.co/ym1xrN7wld. Method shown to be precise, accurate and robust. Applicable to API and formulation, suitable for large scale manufacture and for regulatory submissions.

[MediBeacon @medibeacon]

International Journal of Toxicology published a paper https://t.co/XQlbPibCfK that is the fourth paper in series covering formal nonclinical assays completed on fluorescent tracer agent Relmapirazin (MB-102). Access MediBeacon peer-reviewed publications at https://t.co/32htMua5Vg